371 related items for PubMed ID: 17584314
1. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease.
Kuo HC, Yang KD, Liang CD, Bong CN, Yu HR, Wang L, Wang CL.
Pediatr Allergy Immunol; 2007 Jun; 18(4):354-9. PubMed ID: 17584314
[Abstract] [Full Text] [Related]
2. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[Abstract] [Full Text] [Related]
3. Immunoglobulin failure and retreatment in Kawasaki disease.
Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C.
Pediatr Cardiol; 2003 Dec; 24(2):145-8. PubMed ID: 12457253
[Abstract] [Full Text] [Related]
4. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM, Silverman ED, McCrindle BW, Yeung RS.
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[Abstract] [Full Text] [Related]
5. Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease.
Kuo HC, Wang CL, Liang CD, Yu HR, Huang CF, Wang L, Hwang KP, Yang KD.
Pediatr Allergy Immunol; 2009 May; 20(3):266-72. PubMed ID: 19438983
[Abstract] [Full Text] [Related]
6. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[Abstract] [Full Text] [Related]
7. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
[Abstract] [Full Text] [Related]
8. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[Abstract] [Full Text] [Related]
9. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease.
Sittiwangkul R, Pongprot Y, Silvilairat S, Phornphutkul C.
Singapore Med J; 2006 Sep; 47(9):780-4. PubMed ID: 16924360
[Abstract] [Full Text] [Related]
10. Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease.
Kashef S, Safari M, Amin R.
Kaohsiung J Med Sci; 2005 Sep; 21(9):401-4. PubMed ID: 16248123
[Abstract] [Full Text] [Related]
11. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease.
Abe J, Ebata R, Jibiki T, Yasukawa K, Saito H, Terai M.
J Allergy Clin Immunol; 2008 Nov; 122(5):1008-1013.e8. PubMed ID: 18930517
[Abstract] [Full Text] [Related]
12. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
Sangtawesin C, Kirawitaya T, Layangkool T, Nawasiri W, Vimolsarawong N.
J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163
[Abstract] [Full Text] [Related]
13. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease.
Kuo HC, Liang CD, Wang CL, Yu HR, Hwang KP, Yang KD.
Acta Paediatr; 2010 Oct; 99(10):1578-83. PubMed ID: 20491705
[Abstract] [Full Text] [Related]
14. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.
Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, Matsuishi T.
J Pediatr; 2006 Aug; 149(2):237-40. PubMed ID: 16887442
[Abstract] [Full Text] [Related]
15. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
Kuo HC, Wang CL, Liang CD, Yu HR, Chen HH, Wang L, Yang KD.
J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
[Abstract] [Full Text] [Related]
16. Both patient characteristics and IVIG product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease.
Khan S, Doré PC, Sewell WA.
Pediatr Allergy Immunol; 2008 Mar; 19(2):186-7. PubMed ID: 18257907
[No Abstract] [Full Text] [Related]
17. Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease.
Tsujimoto H, Takeshita S, Nakatani K, Kawamura Y, Tokutomi T, Sekine I.
Clin Immunol; 2002 May; 103(2):161-8. PubMed ID: 12027421
[Abstract] [Full Text] [Related]
18. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
Sato S, Kawashima H, Kashiwagi Y, Hoshika A.
Int J Rheum Dis; 2013 Apr; 16(2):168-72. PubMed ID: 23773640
[Abstract] [Full Text] [Related]
19. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
DU ZD, Zhao D, DU JB, Lu S, Yi JM, Hou AC, Zhou ZS, Ding GF, Beijing Kawasaki Disease Epidemilogy Study Grou.
Zhonghua Yi Xue Za Zhi; 2007 Nov 27; 87(44):3119-21. PubMed ID: 18269869
[Abstract] [Full Text] [Related]
20. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.
Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A.
Circulation; 2006 Jun 06; 113(22):2606-12. PubMed ID: 16735679
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
